These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 18413839)

  • 1. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
    Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
    Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
    Spector NL; Xia W; Burris H; Hurwitz H; Dees EC; Dowlati A; O'Neil B; Overmoyer B; Marcom PK; Blackwell KL; Smith DA; Koch KM; Stead A; Mangum S; Ellis MJ; Liu L; Man AK; Bremer TM; Harris J; Bacus S
    J Clin Oncol; 2005 Apr; 23(11):2502-12. PubMed ID: 15684311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
    Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
    Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
    Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
    Avizienyte E; Ward RA; Garner AP
    Biochem J; 2008 Oct; 415(2):197-206. PubMed ID: 18588508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
    Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
    Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
    J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
    Li G; Wang X; Hibshoosh H; Jin C; Halmos B
    PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ba/F3 cells and their use in kinase drug discovery.
    Warmuth M; Kim S; Gu XJ; Xia G; Adrián F
    Curr Opin Oncol; 2007 Jan; 19(1):55-60. PubMed ID: 17133113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
    Lu J; Zhou K; Yin X; Xu H; Ma B
    Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
    Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
    Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
    Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
    Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.